Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.55 |
| ▸ | CA1 | P00915 | 3/20 | 0.55 |
| ▸ | CA2 | P00918 | 3/20 | 0.55 |
| ▸ | CA7 | P43166 | 3/20 | 0.55 |
| ▸ | CA9 | Q16790 | 3/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | XDH | P47989 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17545110 | 0.91 | KDM4E (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL17544615 | 0.91 | CA12 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL17789604 | 0.91 | KDM4E (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL18977859 | 0.91 | KDM4E (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1425020 | 0.89 | ALDH1A1 (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30295698 | 0.89 | ALDH1A1 (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL21971567 | 0.89 | KDM4E (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3511223 | 0.88 | ALDH1A1 (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28175165 | 0.88 | KDM4E (0.71) | CA12CA1CA2CA7CA9 | |
| SCHEMBL17544754 | 0.88 | KDM4E (0.51) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026104409-A1 | MULTIMERIC MANGANESE CONTRAST AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2026-05-21 | — | — | WO | disclosed |
| EP-4741400-A1 | MULTIMERIC MANGANESE CONTRAST AGENTS | Bayer Aktiengesellschaft (DE) | 2026-05-13 | — | — | EP | disclosed |
| US-11524969-B2 | Pyrrolobenzodiazepines and conjugates thereof as antitumour agents | MEDIMMUNE LIMITED (GB) | 2022-12-13 | — | — | US | disclosed |
| US-11278627-B2 | Antibody-drug conjugates and the use of same in therapy | MC SAF (FR) | 2022-03-22 | — | — | US | disclosed |
| US-20210079023-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF AS ANTITUMOUR AGENTS | MEDIMMUNE LIMITED (GB) | 2021-03-18 | — | — | US | disclosed |
| EP-3521314-B1 | ANTIBODY-DRUG CONJUGATES AND USE THEREOF IN THERAPY | MC SAF (FR) | 2021-02-24 | — | — | EP | disclosed |
| US-10597409-B2 | Water-soluble triazapyridinophane-based complexing agents and corresponding fluorescent lanthanide complexes | CISBIO BIOASSAYS (FR) | 2020-03-24 | — | — | US | disclosed |
| EP-3386974-B1 | WATER-SOLUBLE TRIAZAPYRIDINOPHANE-BASED COMPLEXING AGENTS AND CORRESPONDING FLUORESCENT LANTHANIDE COMPLEXES | CISBIO BIOASSAYS (FR) | 2020-02-05 | — | — | EP | disclosed |
| WO-2019197602-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF AS ANTITUMOUR AGENTS | MEDIMMUNE LIMITED (GB) | 2019-10-17 | — | — | WO | disclosed |
| EP-3521314-A1 | NEW ANTIBODY-DRUG CONJUGATES AND USE THEREOF IN TREATMENT | Université François Rabelais (FR) | 2019-08-07 | — | — | EP | disclosed |
| US-20160151515-A1 | NOVEL ANTIBODY-DRUG CONJUGATES AND THE USE OF SAME IN THERAPY | MC SAF (FR) | 2016-06-02 | — | — | US | disclosed |
| US-20160151515-A1 | NOVEL ANTIBODY-DRUG CONJUGATES AND THE USE OF SAME IN THERAPY | MC SAF (FR) | 2016-06-02 | — | — | US | disclosed |
| US-20160102096-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | EPITHERAPEUTICS APS | 2016-04-14 | — | — | US | disclosed |
| US-20160102096-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | EPITHERAPEUTICS APS | 2016-04-14 | — | — | US | disclosed |
| US-20160102096-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | EPITHERAPEUTICS APS | 2016-04-14 | — | — | US | disclosed |
| WO-2016033169-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | EPITHERAPEUTICS APS (US) | 2016-03-03 | — | — | WO | disclosed |
| WO-2016033169-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | EPITHERAPEUTICS APS (US) | 2016-03-03 | — | — | WO | disclosed |
| WO-2015004400-A1 | NOVEL ANTIBODY-DRUG CONJUGATES AND THE USE OF SAME IN THERAPY | UNIVERSITE FRANCOIS RABELAIS (FR) | 2015-01-15 | — | — | WO | disclosed |
| WO-2012153253-A2 | AROMATIC COMPOUNDS AND METAL COMPLEXES THEREOF | DU PREEZ JAN GYSBERT HERMANUS (ZA) | 2012-11-15 | — | — | WO | disclosed |
| EP-0533131-B1 | Process for selectively mono-ortho-hydroxy alkylation of 4-substituted pyridine derivatives | HOECHST AG (DE) | 1995-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524969-B2 | Pyrrolobenzodiazepines and conjugates thereof as antitumour agents | PBRM1, HDAC6, NPM1 | CA12 861/4885CA1 1324/4885CA2 3094/4885 |
| US-20210079023-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF AS ANTITUMOUR AGENTS | PBRM1, HDAC6, NPM1 | CA12 861/4885CA1 1324/4885CA2 3094/4885 |
| US-20160102096-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | PHF8, KDM3A, PHF2 | CA12 2940/4885CA1 1809/4885CA2 1968/4885 |
| US-20160151515-A1 | NOVEL ANTIBODY-DRUG CONJUGATES AND THE USE OF SAME IN THERAPY | CD47, TNFRSF9, VSIG8 | CA12 921/4885CA1 1552/4885CA2 4511/4885 |
| US-10597409-B2 | Water-soluble triazapyridinophane-based complexing agents and corresponding fluorescent lanthanide complexes | GSTA1, CLIC1, SLC40A1 | CA12 1289/4885CA1 856/4885CA2 990/4885 |
| US-11278627-B2 | Antibody-drug conjugates and the use of same in therapy | CD47, TNFRSF9, VSIG8 | CA12 689/4885CA1 1035/4885CA2 4304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.